trilostane
Trade name: modrastane
Approved
Dec 31, 1984
Trilostane is a synthetic steroid, which interferes with the formation of both cortisol and aldosterone. It is an inhibitor of 3 beta-hydroxysteroid dehydrogenase. This drug under trade name MODRASTANE was withdrawn from human use in the United States market. But marketed under the trade names Modrenal and is already approved in the United Kingdom for the treatment of advanced post-menopausal breast cancer and Cushing 's disease. In addition, this drug has been successfully developed and marketed for veterinary use in the United Kingdom under the trade name Vetoryl. — NCATS
Clinical trial activity
2 trials · 3 clinical orgs · 2 marketing orgs
Earliest trial started Mar 1, 2004 (NCT00181597)
Timeline
1980s
- Jun 1, 1984
Sterling-Winthrop — First NDA Organization
- Jun 1, 1984
Sterling-Winthrop — NDA Organization
- Dec 31, 1984
Earliest FDA Approval
- Dec 31, 1984
Bioenvision — Marketing Organization
- Dec 31, 1984
Bioenvision — NDA Secondary Org
2000s
- Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
Approval history
- approvedDec 31, 1984
Chemistry & pharmacology
SMILES
C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(O)=C(C[C@]35C)C#N)[C@@H]1CC[C@@H]2O- Mol. weight
- 329.4333 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaTrilostane ↗
- NCATSL0FPV48Q5R ↗
- ChEMBLCHEMBL1200907 ↗
Also known as
- 4alpha,5-epoxy-17beta-hydroxy-3-oxoandrostane-2-carbonitrile
- desopan
- modrastane
- modrastane
- modrastane
- modrastane
- modrefen
- modrenal
- modrenal
- modrenal
- modrenal
- trilostane
- trilostane
- trilostane
- trilostane
- trilostane
- trilostane
- trilostane
- trilostane
- trilostane
- trilostane
- trilostane
- trilostane
- trilostano
- trilostano
- trilostanum
- trilostanum
- win 24,540
- win-24540
- win-24540
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01615211 | Phase 2 | May 1, 2012 | Karolinska Institute, The University of Hong Kong |
| NCT00181597 | Phase 2 | Mar 1, 2004 | Genzyme |
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genzyme | For profit | 1 | 1 | 1 | 2004 |
| Karolinska Institute | Academic/Hospital | 1 | 1 | 1 | 2012 |
| The University of Hong Kong | Academic/Hospital | 1 | 0 | 1 | 2012 |
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Bioenvision | For profit | MKTG | Dec 31, 1984 |
| Bioenvision | For profit | NDA2 | Dec 31, 1984 |
| Sterling-Winthrop | For profit | NDA | Jun 1, 1984 |